Clin Res Cardiol (2021). 10.1007/s00392-021-01933-9

Diagnostic Capacity of MR-proANP in Systolic Heart Failure assessed byEchocardiography

M. Harbrücker1, M. Natale1, S.-H. Kim1, S. Lindner1, T. Bertsch2, T. Roth3, M. Borggrefe1, S. Lang1, I. Akin1, M. Behnes1, für die Studiengruppe: CIBER

1I. Medizinische Klinik, Universitätsklinikum Mannheim, Mannheim; 2Institut für klinische Chemie und Laboratoriumsmedizin und Transfusionsmedizin, Klinikum Nürnberg Nord, Nürnberg; 3Institut für Experimentelle u. Klinische Pharmakologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen;

Purpose: Early diagnosis of systolic heart failure is important to initiate treatmentin time and thus reduce hospitalization and mortality. Novel biomarkers, such asMR-proANP, might aid early diagnosis of left ventricular dysfunction and thusimprove clinical outcomes. This study aims to evaluate the association betweenMR-proANP and left ventricular ejection fraction (LVEF) assessed byechocardiography. Methods: Patients undergoing routine echocardiography were prospectivelyenrolled in the present monocentric study. Patients with right ventriculardysfunction (TAPSE < 17 mm) were excluded. Blood samples for measurementsof MR-proANP and NT-proBNP were collected at the day of echocardiographicexamination. Subgroups based on LVEF grades were defined (0: left ventricularejection fraction (LVEF) > 60 % (n=37); I: LVEF > 55 - ≤ 60% (n=40), II: LVEF> 45 - ≤ 55 % (n=32), III: LVEF > 35- ≤ 45 % (n=22), IV: LVEF ≤ 35 % (n=15). Results: A total of 146 patients were included. Levels of MR-proANP as well asNT-proBNP increased significantly according to decreasing LVEF (MR-proANP:p=0.0001, NT-proBNP: p=0.0001). Furthermore, MR-proANP correlatedsignificantly with LVEF (p=0.0001). Both, MR-proANP and NT-proBNP wereable to discriminate patients with LVEF Grade IV (MR-proANP: AUC=0.795,p=0.0001; NT-proBNP: AUC=0.84, p=0.0001). Conclusions: This study shows the diagnostic capacity of MR-proANP fordetection of impaired left ventricular ejection fraction assessed byechocardiography. MR-proANP might thus be a useful biomarker for the detectionof systolic heart failure.

https://dgk.org/kongress_programme/ht2021/P87.htm